Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
about
Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsThe influence of subclonal resistance mutations on targeted cancer therapyThe GIST of targeted therapy for malignant melanomaHow many molecular subtypes? Implications of the unique tumor principle in personalized medicineThe promise of circulating tumor cell analysis in cancer managementEfficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Current management and prognostic features for gastrointestinal stromal tumor (GIST)Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.A nomogram to predict disease-free survival after surgical resection of GISTA phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialComparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinomaAssessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Molecular basis and management of gastrointestinal stromal tumorsNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.Is there something other than imatinib mesilate in therapeutic options for GIST?Mast cell leukemia associated with undefined morphology and chronic basophilic leukemiaIntegrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumorTumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateDefects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.The role of oncogenes in gastrointestinal cancer.The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.A gist of gastrointestinal stromal tumors: A review.Metastasectomy for gastrointestinal stromal tumors.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
P2860
Q26738567-98613097-FB06-432F-99C4-F1B77167FA45Q26781693-2771FC1E-8B76-4295-9CC1-744AC9EA9F0EQ26827092-562364FA-1211-4F17-A452-3BC76E5EA667Q26992045-F004D6FF-7A7F-4412-802B-7FC89BCD3BB6Q27022113-F085EDF2-98C8-4BC3-8E85-CB59B05C08C7Q27853181-2928DA0C-4AAF-4685-9072-868600E480B4Q28391684-704ADA4F-2A5F-4714-8352-C1AF265FDE8FQ30245586-6456EB98-4D68-4383-A11E-6935698882C0Q30366151-BE992334-60D4-4CAC-BAEC-B0F3D26912EEQ33168544-C6185A0B-5A9D-4ADC-BD59-AE1C0A813F6CQ33274455-EF74F648-748F-4048-AA90-B7B16A9AEE2DQ33612778-0D28A9A9-730F-4BBC-BCEE-E8EAFA51BD42Q33624278-D6FA0B88-4AFA-4125-A442-8BB144542D79Q33633409-CFE19CD8-A3E5-4F0C-9443-E37ED05DFC42Q33644791-56F16818-82C8-4393-B912-8880778BF853Q33699901-AB958208-3C72-40FB-8046-5E7D740E64FBQ33710999-5DB8B1AE-FB9C-48E2-9AB9-D72C8395593EQ33802730-E5C4B4F1-CFC5-4C24-B3BA-7FB9BC91AA13Q33813835-1E92592C-3A64-478F-BBE7-2FADBA2D531FQ33840444-288B9D84-9265-456D-AA0A-A84811B17E6BQ33895608-1A85D7F0-6D51-4ECC-9D78-CEB3EA5451AAQ33903598-F0C7A81F-11B3-4906-8E42-3C991406E991Q33921067-930C15D3-193D-4163-B11E-FCE1DEA4C4DEQ34005890-5BA40B71-9368-4A20-9C5F-E139802C84A4Q34036409-21980BB4-196F-4842-9782-E7DA848D96CCQ34069556-3808F7DA-EFB0-456E-847E-C814E4603D2CQ34102055-69FFC762-8D49-46D0-8114-6B37153B333EQ34163784-C3F32C50-6E06-447C-8CE3-0AFB5C5A7F10Q34207379-AE41C774-7C48-485B-BFE6-9AAC4EFC96EDQ34253316-45F4F1E0-1AEE-49A7-ABC8-D9689A20C134Q34274467-091A6559-7594-4579-AEFD-553670CBE5B3Q34305765-F8D10FDA-415E-465F-BFF9-CAF55C366D22Q34441837-6933E8AD-8E22-4955-A49F-2A84668E9482Q34471702-1C4ED604-C1FD-4D77-B9EF-457360BA0F68Q34616409-C6DA30DA-8016-4D77-9D38-78A73D06FDFFQ34629408-D8403D00-693F-4506-B6F7-3C2AF68257B5Q34645665-225FAFAE-02EB-4B73-A7BA-AD6779FF3CA9Q34654203-30EEA378-4278-43B6-8976-D3120053DC2AQ34656880-F13AC913-AE86-4215-8068-75141DCEA880Q34662946-A0C193DF-6C9B-448B-B2DB-AEC1809587AC
P2860
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@en
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@nl
type
label
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@en
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@nl
prefLabel
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@en
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@nl
P2093
P2860
P356
P1476
Correlation of kinase genotype ...... ia Group B and Southwest Oncol
@en
P2093
Cathryn Rankin
Charles D Blanke
Christopher D M Fletcher
Christopher L Corless
Christopher W Ryan
Donna Hollis
Ernest C Borden
George D Demetri
Jonathan A Fletcher
Kouros Owzar
P2860
P304
P356
10.1200/JCO.2008.17.4284
P407
P577
2008-10-27T00:00:00Z